Redeye provides a research update following the Q2 report published by Lipum earlier today. While the report itself did not include any major surprises, we primarily focus on the recent clinical progress of the company. Following the rights issue and an increased cash position during the spring, Lipum reported positive interim results from the ongoing phase I study. We reiterate our valuation of Lipum with a base case of SEK15.